Integrating medications and brief counseling for alcohol use disorder into hepatology clinics
Feasibility and Acceptability of a Novel Implementation Intervention to Promote Alcohol Use Disorder Treatment in Hepatology Clinics
NA · Yale University · NCT07525258
This project will test a way to help hepatology clinic clinicians provide medicines and short counseling for people with alcohol use disorder and alcohol-associated liver disease.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 30 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Yale University (other) |
| Locations | 1 site (New Haven, Connecticut) |
| Trial ID | NCT07525258 on ClinicalTrials.gov |
What this trial studies
This pilot uses implementation facilitation to help hepatology clinicians routinely offer medications for alcohol use disorder (MAUD) together with brief counseling to patients with alcohol-associated liver disease. The intervention focuses on training, workflow changes, and clinician supports within Yale School of Medicine/YNHH hepatology clinics. Success will be measured by changes in MAUD prescribing, counseling delivery, and uptake among eligible patients. The goal is to make integrated AUD care more accessible and practical in liver clinics.
Who should consider this trial
Good fit: Adults with alcohol use disorder and alcohol-associated liver disease who receive care at participating Yale hepatology clinics are the intended beneficiaries of this project.
Not a fit: Patients who do not receive care at the participating Yale/YNHH hepatology clinics or whose clinicians do not adopt the intervention may not experience any benefit from this pilot.
Why it matters
Potential benefit: If successful, more patients with AUD and ALD could receive effective medications and counseling, which may reduce liver-related complications and improve outcomes.
How similar studies have performed: Similar implementation efforts in primary care and other specialty settings have improved uptake of medications for AUD, but evidence specifically in hepatology clinics is limited.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Must provide care for patients with liver disease at a hepatology clinical location within the Yale School of Medicine and YNHH medical system. Exclusion Criteria: * Providers who do not treat patients with chronic liver disease and alcohol-associated liver disease.
Where this trial is running
New Haven, Connecticut
- Yale School of Medicine/Yale-New Haven Health — New Haven, Connecticut, United States (RECRUITING)
Study contacts
- Principal investigator: Lamia Haque — Yale University
- Study coordinator: Lamia Haque, MD MPH
- Email: lamia.haque@yale.edu
- Phone: (203) 777-0304
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Alcohol Use Disorder, Alcohol-associated Liver Disease, Clinicians, Medications for Alcohol Use Disorder